N-Succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: In vivo study with TNBS-induced colitis model in rats

Mura, Carla; Nácher, Amparo; Merino, Virginia; Merino-Sanjuán, Matilde; Cardá, Carmen; Ruiz, Ana Lúcia Tasca Góis; Manconi, Maria; Loy, Giuseppe; Fadda, Anna Maria; Dı́ez-Sales, Octavio

doi:10.1016/j.ijpharm.2011.06.025

Cited by 32 publications

(29 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a typical formulation, 2 ml of such media was added to 180 mg of P90G, left hydrating overnight and sonicated (25 cycles, 5 seconds on and 2 seconds off, 13 microns of probe amplitude) with a high intensity ultrasonic disintegrator (Soniprep 150, MSE Crowley, London, UK) [21]. The resulting vesicle dispersions were frozen at −80°C and freeze-dried for 24 h at -80°C and 0 mm Hg, using a Freeze-Dryer Criotecnica, (AMCOTA, Rome, Italy) [22]. Each sample was rehydrated with 2 ml of bidistilled water and sonicated (50 cycles, 5 seconds on and 2 seconds off) prior to use.…”

Section: Sample Preparationmentioning

confidence: 99%

Freeze-dried eudragit-hyaluronan multicompartment liposomes to improve the intestinal bioavailability of curcumin

Catalán-Latorre

Ravaghi

Manca

et al. 2016

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

Section: Sample Preparationmentioning

confidence: 99%

Freeze-dried eudragit-hyaluronan multicompartment liposomes to improve the intestinal bioavailability of curcumin

Catalán-Latorre

Ravaghi

Manca

et al. 2016

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

“…The colon targeting of the formulation was improved compared to the non-coated formulation with 56% of 5-ASA in the colon after 10 h and 40% after 24 h. Thus the optimal time-frame for drug release was considered to be 10 to 15 h.. Freeze-drying prepared 5-ASA loaded N-succinyl-chitosan matrixes had a comparable in vivo anti-inflammatory effect to negatively charged spray-dried microparticles (5.1 ± 2.2 µm) [129].…”

Section: Kumbar Et Al Encapsulated Diclofenac Sodium Into Cross-linkmentioning

confidence: 99%

Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs

Serpe¹,

Canaparo²,

Foglietta³

et al. 2013

CPD

View full text Add to dashboard Cite

Pharmaceutical technology has introduced a promising pathway in the future of medicinein particular nanotechnological innovations have provided the opportunity to design and develop efficient drug delivery systems able to target and treat several diseases, including those mediated by inflammation. The engineering of drug delivery systems can be used to target tissues involved in the pathology under treatment, to avoid early drug biological environmental degradation and to modulate drug pharmacokinetics. Glucocorticoids and non-steroidal anti-inflammatory drugs are the most commonly prescribed drug categories worldwide for the treatment of disorders associated with inflammation.Although glucocorticoids can be highly effective in treating inflammation, their systemic application is limited due to the high incidence of serious adverse effects, mainly in long-term treatment. Non-steroidal anti-inflammatory drugs are a heterogeneous group of compounds and most of them have unfavorable pharmacokinetics and pharmacodynamics, leading to adverse effects, such as gastrointestinal disorders. Therefore, the need for drug delivery systems for long term administration of anti-inflammatory drugs witha well-controlled release profile is evident. The aim of this review is to assess innovative colloidal drugs carriers, in particular liposomes and nanoparticles, with special focus on site-specific delivery for particularly problematic tissues such as the gastrointestinal tract, joints and eyes.3

show abstract

“…During this time, various rectal and oral formulations have been developed. Such a drug targeting strategy is needed for its topical action and especially because local concentrations in the mucosa will determine the clinical outcome (Mura et al, 2011;Collnot et al, 2012;Huttunen et al, 2013;Shaikh et al, 2013;Wolk et al, 2013). Unfortunately, its clinical application was greatly limited by the great gastrointestinal stimulation.…”

Section: Introductionmentioning

confidence: 99%

Novel pH-sensitive hydrogels for 5-aminosalicylic acid colon targeting delivery:in vivostudy with ulcerative colitis targeting therapy in mice

et al. 2015

View full text Add to dashboard Cite

(2016) Novel pH-sensitive hydrogels for 5-aminosalicylic acid colon targeting delivery: invivo study with ulcerative colitis targeting therapy in mice, Drug Delivery, 23:6, 1926-1932, DOI: 10.3109/10717544.2014 The Central Hospital of Xi' an Huashan, Xi' an, China AbstractCurrent guidelines recommend patients with active and mild-to-moderate ulcerative colitis (UC), who have received initial therapy with 5-aminosalicylic acid (5-ASA). In this study, a novel drug delivery vehicle achieved by pH-sensitive hydrogels was applied to 5-ASA. In our previous work, a novel P(CE-MAA-MEG) pH-sensitive hydrogel was successfully synthesized by the heatinitiated free radical polymerization method. The aim of this study is to investigate its sitespecific delivering of drugs to the colon and evaluate its colon-targeting characteristic in vivo. 5-ASA was chosen as a model drug and successfully loaded in the hydrogel. In vitro investigations were carried out to evaluate its release process. Above all, animal treatment results reveal an obvious effect on the UC healing. Therefore, all results suggested that the developed 5-ASA-P(CE-MAA-MEG) hydrogel (5-ASA-GEL) as a colon-targeting vector might have a great potential application in the UC therapy.

show abstract

N-Succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: In vivo study with TNBS-induced colitis model in rats

Cited by 32 publications

References 33 publications

Freeze-dried eudragit-hyaluronan multicompartment liposomes to improve the intestinal bioavailability of curcumin

Freeze-dried eudragit-hyaluronan multicompartment liposomes to improve the intestinal bioavailability of curcumin

Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs

Novel pH-sensitive hydrogels for 5-aminosalicylic acid colon targeting delivery:in vivostudy with ulcerative colitis targeting therapy in mice

Contact Info

Product

Resources

About